Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well ibrutinib and blinatumomab work in treating patients
with B acute lymphoblastic leukemia that has come back or is not responding to treatment.
Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell
growth. Monoclonal antibodies, such as blinatumomab, may interfere with the ability of cancer
cells to grow and spread. Giving ibrutinib and blinatumomab may work better in treating
patients with relapsed or refractory B acute lymphoblastic leukemia.
Phase:
Phase 2
Details
Lead Sponsor:
Brian Jonas
Collaborators:
National Cancer Institute (NCI) Pharmacyclics LLC.